InvestaMatch’s Post

🌿CANNABIS FUND RAISING AND M&A ACTIVITY REVIEW: 1Q24 This week's Stash report on the cannabis industry for 1Q24 reveals a significant 62% increase in fundraising, led by a surge in equity raises, indicating a rejuvenated investor interest possibly spurred by optimistic regulatory expectations. The analysis points out that Cultivation & Retail and Psychedelics were leading sectors in fundraising, with M&A activities hitting a low but expected to rebound due to improving business fundamentals and a widening valuation gap between larger and smaller operators. The report suggests an optimistic future for the cannabis industry's capital market activities, driven by regulatory developments and a recovering market environment. Read the full report and follow us for more updates. Contact us for more information: 📧 info@intro-act.com 📞 617-454-1088 🌐 www.intro-act.com #CannabisIndustry #CannabisInvesting #CultivationAndRetail #CannabisMandA #EquityFundingCannabis #CannabisStartups #MedicalCannabis #CannabisTech #CannabisStocks #InvestInCannabis #CannabisVC #CannabisEquity #CannabisCapital #CannabisMarketTrends #CannabisEntrepreneurs #CannabisFundingOpportunities

💹💰 It may be June, but the UK hasn't quite got the memo about the summer weather. So I'm back to warm you up with an impressive #financialfriday wrap up this week. The money keeps rolling in for the Biotech industry as we head towards the half year mark, so watch below for an overview of this weeks deals: 💵 Alzheon, Inc. | Preserving Future Memories $100 million series E 💳 Amber Therapeutics $100 million series A 💷 Bright Peak Therapeutics $90 million series C 💸 Prolific Machines, Inc. $55 million series B1 💲 Adcytherix €30 million seed funding #financialfriday #biotechinvestment #venturecapitalist #vcinvestment

Private investments in Public Entities (PIPEs) are providing needed capital for the biotechnology space. There have been 30 PIPE transactions involving public biotechs and institutional investors (mostly hedge funds) that have raised $4 billion in the first two months of the year. #capitalraising #biotechnology

There is certainly a rising sense of optimism in the air about the #lifesciences & #biotech markets. After a flat 2023, 2024 is shaping up to be flush with activity. It’s interesting to read the hopeful perspectives shared by Maha Katabi, PhD, CFA of Sofinnova Investments in this interview. Among her insights: “The deal flow — it’s never been any better. Probably that’s a function of how public markets have corrected. A lot more companies are interested in exploring more fully the availability of capital in private markets before going down the IPO path.”  #executivesearch  

Evergrowth BioHealthcare Capital: Outstanding Results Since Launch launched on November 15, 2023. As of April 01 2024, the fund had returned over 51.30%, surpassing the SPDR S&P 500 ETF Trust (SPY), the Nasdaq Biotechnology Index (NBI), and the Dow Jones Industrial Average (INDU) by a wide margin. To give patients hope throughout the globe, Evergrowth invests in cutting-edge preclinical, clinical and early product-stage publicly traded biotech firms. The fund is positioned to provide investors with greater returns over the long run by outperforming market benchmarks. The Evergrowth performance data highlights the following important points: Since beginning operations, the fund has returned more than 51.30%. • The SPDR S&P 500 ETF Trust, the Nasdaq Biotechnology Index, and the Dow Jones Industrial Average have all underperformed the fund. • Evergrowth BioHealthcare Capital makes investments in cutting-edge public biotech firms in pre-trial, trial and early product stages. • Disclaimer: This unaudited record is for informational purposes only. Past performance does not guarantee future results Find out if you're a good fit at Evergrowth BioHealthcare Capital #investing #finance #biotech #healthcare

📈 Private investments in public equity (PIPEs) are making a strong comeback in 2024. 🚀 By late May, PIPE deal transactions have tripled 2023’s total and surpassed 2022. This resurgence is crucial for biopharma companies as PIPEs provide easier capital access vs. traditional public offerings—underscoring the sector’s growing investor confidence in biopharma innovation. Read more here: https://bit.ly/3wTfXBL #Biopharma #Investments #PIPEs #CapitalRaising #Finance #Innovation #Biotechnology

Regeneus trebles on back of merger deal This week’s Bulls N’ Bears ASX Runners of the Week is dominated by biotechs, with two showing big gains for punters. Line honours go to… Regeneus Ltd. Take a look at the full article here - The Sydney Morning Herald Regeneus Ltd - https://lnkd.in/e2BPwhXW #biotech #biotechnology #biology #technology

A sobering assessment of London’s AIM market from my BioCentury Inc. colleague Stephen Hansen, following the recent de-listings of three U.K. biotechs. 💬 “Anybody who lists on AIM should not be surprised that there’s low liquidity and they can’t raise secondary financing.” - Tim Haines of Abingworth 💬 ✅ Full analysis: https://lnkd.in/d5VNEEKG #biotech #capitalmarkets

Here’s the Latest Announcements from Today! Check out the latest updates from companies on Liquidity. Follow your favourite companies and get ASX Announcement Highlights, tailored just for you, delivered direct to your inbox. Recharge Metals Limited | $REC Pointerra | $3DP Wide Open Agriculture | $WOA Structural Monitoring Systems Plc | $SMN Buxton Resources | $BUX Chariot Corporation Ltd | $CC9 Argenica Therapeutics | $AGN Strategic Elements Ltd | $SOR Parkd | $PKD 🔗 - https://lnkd.in/gMUKDxdF #Liquidity #ASX #Investing #Announcements #MarketUpdates #InvestmentNews

Epoch 2: Biotech Poised for 2024 Recovery 👉First financing valuations 👉VC investment size and deal activity 👉Investment by indication 👉Most active biotech investors 👉Insider round prevalence 👉Avg valuations by round 👉Pharma VC impact on valuations 👉Private M&A 👉Techbio landscape 👉Techbio deal sizes 👉Techbio step-ups https://lnkd.in/dEkBy2bY